Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730819 · ClinicalTrials.gov registry record · Phase 2
Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma
A Phase 2 study of Melasma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 2
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT02730819 is a Phase 2 study of Melasma that has completed, run by Mayo Clinic. The registered enrollment target is 19 participants, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (56% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02730819, a Phase 2 study of Melasma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to gather information on the effectiveness and tolerability of a novel composition of existing U.S. Food and Drug Administration (FDA) approved topical medications for the treatment of moderate to severe melasma.
Conditions Studied
Interventions
- DRUG Illuminate Cream
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2016-05-15 |
| Est. Completion | 2016-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730819
The ClinicalTrials.gov registry entry for NCT02730819 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 43-participant average among 8 other Melasma trials with a reported enrollment target (56% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melasma appearing as the primary indexed condition, and to 1 intervention - of which Illuminate Cream is the first listed.
NCT02730819 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT02730819 about?
NCT02730819 is a clinical study titled "Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma". The purpose of this research study is to gather information on the effectiveness and tolerability of a novel composition of existing U.S. Food and Drug Administration (FDA) approved topical medications for the treatment of moderate to severe melasma.
What is the current status of trial NCT02730819?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 19 participants. The study started on 2016-05-15. Estimated completion is 2016-12-30.
What conditions does trial NCT02730819 study?
This clinical trial studies the following conditions: Melasma.
What interventions are being tested in trial NCT02730819?
The interventions under investigation include: Illuminate Cream (DRUG).
Who is sponsoring clinical trial NCT02730819?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02730819 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melasma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma
RECRUITING · NA
-
The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis
RECRUITING · NA
-
LaseMD System for the Treatment of Melasma
ACTIVE NOT RECRUITING · NA
-
Salicylic Acid Peels Combined With 4% Hydroquinone in the Treatment of Moderate to Severe Melasma in Hispanic Women
COMPLETED · Phase 4
-
Efficacy and Safety of PiQo4 Device for Treatment of Melasma
COMPLETED · NA
-
Split-face Study Comparing the Cosmetic Efficacy and Tolerability of Two Topical Products in Participants With Moderate Facial Melasma
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.